Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial

International Journal of Gynecological Cancer

Volumn 26, Issue 5, 2016, Pages 898-905

  González Martín, Antonio ^a   Pautier, Patricia ^b   Mahner, Sven ^c   Rau, Joern ^d   Colombo, Nicoletta ^e   Ottevanger, Petronella ^f   Del Campo, Josep M ^g   Selle, Frédéric ^h   Du Bois, Andreas ⁱ   Gadducci, Angiolo ^j   García, Yolanda ^k   Berton Rigaud, Dominique ^l   Marmé, Frederik ^m   Ortega, Eugenia ⁿ   Martin, Nicolas ^o   Bastiere Truchot, Lydie ^p   Kiermaier, Astrid ^q   Kurzeder, Christian ⁱ  

^a MD ANDERSON CANCER CENTER   (Spain)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HÔPITAL TENON   (France)

ⁱ KLINIKEN ESSEN MITTE   (Germany)

^j UNIVERSITY OF PISA   (Italy)

^k HOSPITAL DE SABADELL   (Spain)

^l INECO and Medical Oncology Department   (France)

^m UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁿ HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^o Global Medical Affairs Biometrics   (Spain)

^p F HOFFMANN LA ROCHE LTD   (Switzerland)

^q F Hoffmann La Roche   (Switzerland)

more..

Author keywords

HER3; Ovarian cancer; Pertuzumab; Phase 3; Platinum resistant

Indexed keywords

PACLITAXEL; PERTUZUMAB; TOPOTECAN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; GEMCITABINE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; INTESTINE OBSTRUCTION; LOADING DRUG DOSE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREMOR; VOMITING; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESISTANCE; MIDDLE AGED; OVARIAN NEOPLASMS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; TOPOTECAN;

EID: 84973322877     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000695     Document Type: Article

References (18)

1. YanM, Parker BA, Schwab R, et al. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014;40:770-780.
2. Pfisterer J, du Bois A, Bentz EK, et al. Prognostic v alue of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first line chemotherapy. A retrospective evaluation of the AGO-OVAR 3 trial by the AGO OVAR Germany. Int J Gynec ol Cancer. 2009;19:109-115.
3. Tanner B, Hasenclever D, Stern K, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006;24: 4317-4323.
4. Base lga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9: 463-475.
5. Kristjansdottir K, Dizon D. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers. Expert Opin Biol Ther. 2010;10:243-250.
6. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-119.
7. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-734.
8. Mullen P, Cameron DA, Hasmann M, et al. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther. 2007;6:93-100.
9. Nagumo Y, Faratian D, Mullen P, et al. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Mol Cancer Res. 2009;7:1563-1571.
10. Makhija S, Amler LC, Glenn D, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010;28:1215-1223.
11. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J C lin Oncol. 2006;24:4324-4332.
12. Erratum in: J Clin Oncol. 2008;26:2793.
13. Kaye SB, Poole CJ, Dacska-Bidzicska A, et al. A randomized phase II study evaluating the combination of carbop latin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol. 2013;24:145-152.
14. Amler LC. HER3 mRNA as a predicti ve biomarker in anticancer therapy. Expert Opin Biol Ther. 2010;10: 1343-1355.
15. Davis A,Tinker AV,Friedlander M. ' 'Platinum resistant'' ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014 133 624-631.
16. Drucker AM, Wu S, Dang CT, et al. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-Analysis. Breast Cancer Res Treat. 2012;135:347-354.
17. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302-1308.
18. Kurzeder C, Del Campo JM, Pautier P, et al. PENELOPE/AGO-OVAR 2.20: a double-blind placebo-controlled randomized phase III ENGOT trial evaluating chemo therapy with or without pertuzumab for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32(5s): Abstract TPS5613.